SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN

Background: Sovaldi, Ribavirin and PEG-Interferon is gold standard therapy for chronic HEP-C patients. It

is recommended both for treatment naive and experienced patients. We evaluated the safety and

efficacy of this combination in naïve chronic HEP-C G3 patients.

Methods: We prospectively enrolled 50 chronic HEP-C G3 treatment naïve patients.

Patients with de-compensated cirrhosis, platelets count<100, portal vein size >13 mm on ultrasound in

size were excluded.

Eligible patients were enrolled to receive Sovaldi 400mg daily, Ribavirin 10 mg/Kg body weight and

Pegylated interferon 1.5 UCG/KG body weight for 12 weeks.

Patients were seen in outpatient 4-weekly basis. They had baseline CBC, TSH, Blood Sugar, HCV

Genotype, and HCVPCR quantitative. Each patient had CBC at every 4 weeks. RVR at treatment week 4,

and ETR (End of Treatment) at weeks 12 were defined by HCV RNA <25 IU/mL.

Results: This is our ongoing study we are presenting interim analysis of 50 patients who have

completed 12 weeks of treatment.

Out of 50 patients 75% were male, 25 % were female with median age 48 years. 48 patients out of 100

(96%) were PCR negative at week 4 and 96% were PCR negative at week 12 respectively. Two patients

did not achieve RVR, and they did not achieve ETR either.

The most common AEs were nausea, fatigue, dizziness.

Conclusions: Sofosbuvir + Ribavirin+PEG INF in HCV-G3 infected patients are very effective treatment.

Most patients achieved rapid Virologic response without any major side effects. These patients are

under regular review to monitor SVR.